EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping

Alexander J Schubert iD, Qiyao Meng, Joshua Hoffmann, Josefine Rau, Fabian Abele, Robert Greensmith, Carlos Cordero, Antonia Ibel, Julia M Mandler, Kai-Uwe Eckardt, Jan Halbritter, Anand S Dighe und 5 weitere

ACS Sensors · 24.07.2026 · 11 (7) · 5970-5982

DOI: 10.1021/acssensors.6c00841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Sensors, online erschienen am 25.06.2026. Verfasst von Alexander J Schubert und 16 weiteren Autor:innen. Beteiligte Einrichtung: Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin10115, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Point-of-Care Systems, Genotyping Techniques, CRISPR-Cas Systems. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Deutsches Zentrum für Herz-Kreislaufforschung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetic testing enables personalized drug dosing by accounting for genetic variation in drug metabolism. Although there is increasing evidence that genetically guided dosing improves therapeutic efficacy and reduces adverse effects, clinical implementation remains limited as genotyping methods suffer from slow turnaround times and are not optimized for point-of-care use. Here, we present a rapid, multiplexed CRISPR-based assay for genotyping the key CYP2C19 polymorphisms *2, *3, and *17. These variants can alter enzyme activity, impacting the metabolism of drugs such as clopidogrel and mavacamten. Our assay combines isothermal amplification with a dual guide RNA detection strategy, where LwaCas13a selectively detects mutant alleles and LbaCas12a identifies wild-type alleles. In a validation study of 110 participants, the assay showed high concordance with Sanger sequencing, the current gold standard, with variant-specific accuracies of 97.3% (*2), 100% (*3), and 99.1% (*17), demonstrating robust performance across a diverse clinical cohort. The workflow supports both column-based DNA extraction and a simplified, crude extraction protocol. Genotyping results are obtained through either fluorescence detection or multi-analyte lateral-flow readouts, allowing visual interpretation of genotypes with minimal equipment. In conclusion, our findings show that CRISPR-based genotyping can deliver accurate CYP2C19 pharmacogenetic testing, facilitating broader adoption of genotype-guided drug dosing. Furthermore, the programmability of CRISPR-Cas systems enables adaptation to other pharmacogenetic targets relevant to drug metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Point-of-Care SystemsGenotyping TechniquesCRISPR-Cas SystemsPharmacogeneticsClustered Regularly Interspaced Short Palindromic RepeatsHumansGenotypeClopidogrelRapid Diagnostic Tests

Stichwörter der Autor:innen

CRISPR-based diagnosticsCYP2C19 genotypingLbaCas12aLwaCas13aclopidogrelisothermal amplificationmavacamtenmulti-analyte lateral-flow readout

Substanzen

Cytochrome P-450 CYP2C19CYP2C19 protein, humanClopidogrel

Autor:innen und Institutionen

  • Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin10115, Germany.
  • Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin10117, Germany.
  • Berlin Institute of Health , Berlin10117, Germany.
  • School of Medicine and Health, Klinikum rechts der Isar, Department of Neurology, Technical University of Munich, Munich81675, Germany.
  • Renal Division, Department of Medicine, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg79106, Germany.
  • Harvard Medical School , Boston, Massachusetts02115, United States.

ORCID-Profile: Alexander J Schubert, Michael M Kaminski

Förderung

  • NIDDK NIH HHS
  • Deutsches Zentrum für Herz-Kreislaufforschung
  • Deutsche Forschungsgemeinschaft
  • Charité - Universitätsmedizin Berlin
  • Berlin Institute of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Charité – Universitätsmedizin Berlin

Zitieren

APA

Schubert, A. J., Meng, Q., Hoffmann, J., Rau, J., Abele, F., Greensmith, R., Cordero, C., Ibel, A., Mandler, J. M., Eckardt, K. U., Halbritter, J., Dighe, A. S., Tan, X., Hwang, D. Y., Petzold, T., Enghard, P., & Kaminski, M. M. (2026). CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping. ACS Sensors, 11(7), 5970-5982. https://doi.org/10.1021/acssensors.6c00841

Vancouver

Schubert AJ, Meng Q, Hoffmann J, Rau J, Abele F, Greensmith R, et al. CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping. ACS Sensors. 2026;11(7):5970-5982. doi:10.1021/acssensors.6c00841

BibTeX
@article{Schubert2026,
  author = {Schubert, Alexander J and Meng, Qiyao and Hoffmann, Joshua and Rau, Josefine and Abele, Fabian and Greensmith, Robert and Cordero, Carlos and Ibel, Antonia and Mandler, Julia M and Eckardt, Kai-Uwe and Halbritter, Jan and Dighe, Anand S and Tan, Xiao and Hwang, Daw-Yang and Petzold, Tobias and Enghard, Philipp and Kaminski, Michael M},
  title = {CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping},
  journal = {ACS Sensors},
  year = {2026},
  volume = {11},
  number = {7},
  pages = {5970--5982},
  doi = {10.1021/acssensors.6c00841}
}
Kostenlos starten →